Building the Foundation for a New Era of Quadruple Therapy in Heart Failure

Affiliations

Editorial

G Michael Felker. Circulation. 2020.

. 2020 Jan 14;141(2):112-114.

doi: 10.1161/CIRCULATIONAHA.119.044578. Epub 2019 Nov 17.

¹ Duke University School of Medicine and Duke Clinical Research Institute, Durham, NC.

No abstract available

Keywords: Editorials; drug therapy; guideline; heart failure.

Comment on

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF.
Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang CE, Tereshchenko S, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Ponikowski P, Sabatine MS, DeMets DL, Dutkiewicz-Piasecka M, Bengtsson O, Sjöstrand M, Langkilde AM, Jhund PS, McMurray JJV. Martinez FA, et al. Circulation. 2020 Jan 14;141(2):100-111. doi: 10.1161/CIRCULATIONAHA.119.044133. Epub 2019 Nov 17. Circulation. 2020. PMID: 31736328 Clinical Trial.
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.
Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, Nicolau JC, Merkely B, Kitakaze M, DeMets DL, Inzucchi SE, Køber L, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Bengtsson O, Lindholm D, Niklasson A, Sjöstrand M, Langkilde AM, McMurray JJV. Kosiborod MN, et al. Circulation. 2020 Jan 14;141(2):90-99. doi: 10.1161/CIRCULATIONAHA.119.044138. Epub 2019 Nov 17. Circulation. 2020. PMID: 31736335 Free PMC article. Clinical Trial.